ES2572750T3 - Un medicamento que comprende pilocarpina y dapiprazol - Google Patents
Un medicamento que comprende pilocarpina y dapiprazol Download PDFInfo
- Publication number
- ES2572750T3 ES2572750T3 ES08861490.4T ES08861490T ES2572750T3 ES 2572750 T3 ES2572750 T3 ES 2572750T3 ES 08861490 T ES08861490 T ES 08861490T ES 2572750 T3 ES2572750 T3 ES 2572750T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmacologically active
- combination
- active agents
- medicament
- agents according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 title claims abstract description 14
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 title claims abstract description 14
- RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 229960002947 dapiprazole Drugs 0.000 title claims abstract description 14
- 229960001416 pilocarpine Drugs 0.000 title claims abstract description 14
- 239000013543 active substance Substances 0.000 claims abstract description 37
- 208000001491 myopia Diseases 0.000 claims abstract description 20
- 230000004379 myopia Effects 0.000 claims abstract description 15
- 201000010041 presbyopia Diseases 0.000 claims abstract description 14
- 230000004297 night vision Effects 0.000 claims abstract description 10
- 201000006318 hyperopia Diseases 0.000 claims abstract description 9
- 230000004305 hyperopia Effects 0.000 claims abstract description 9
- 201000009310 astigmatism Diseases 0.000 claims abstract description 8
- 230000004304 visual acuity Effects 0.000 claims abstract description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 37
- 230000007547 defect Effects 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000004438 eyesight Effects 0.000 description 24
- 210000001508 eye Anatomy 0.000 description 22
- 230000002889 sympathetic effect Effects 0.000 description 21
- 239000000556 agonist Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 229940012356 eye drops Drugs 0.000 description 15
- 239000011521 glass Substances 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 12
- 230000001734 parasympathetic effect Effects 0.000 description 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229960003679 brimonidine Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 208000014733 refractive error Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 230000004313 glare Effects 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 229940095437 iopidine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0724558.2A GB0724558D0 (en) | 2007-12-15 | 2007-12-15 | Optical correction |
| GB0724558 | 2007-12-15 | ||
| PCT/GB2008/004129 WO2009077736A2 (en) | 2007-12-15 | 2008-12-15 | Optical correction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2572750T3 true ES2572750T3 (es) | 2016-06-02 |
Family
ID=39048209
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08861490.4T Active ES2572750T3 (es) | 2007-12-15 | 2008-12-15 | Un medicamento que comprende pilocarpina y dapiprazol |
| ES16000001T Active ES2725002T3 (es) | 2007-12-15 | 2008-12-15 | Medicamento que comprende pilocarpina y brimonidina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16000001T Active ES2725002T3 (es) | 2007-12-15 | 2008-12-15 | Medicamento que comprende pilocarpina y brimonidina |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20090156606A1 (pt) |
| EP (3) | EP3031457B1 (pt) |
| CN (1) | CN101969940A (pt) |
| AU (1) | AU2008337350A1 (pt) |
| BR (1) | BRPI0821683B8 (pt) |
| CA (1) | CA2747095C (pt) |
| ES (2) | ES2572750T3 (pt) |
| GB (1) | GB0724558D0 (pt) |
| WO (1) | WO2009077736A2 (pt) |
| ZA (1) | ZA201005026B (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2010135731A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| RU2469734C2 (ru) * | 2010-09-02 | 2012-12-20 | Григорий Владимирович Пантелеев | Лечебное средство для лечения расстройств аккомодаций "stiak" |
| RU2630968C2 (ru) | 2011-09-20 | 2017-09-15 | Аллерган, Инк. | Лекарственные средства и способы лечения пресбиопии, умеренной гиперметропии и неправильного астигматизма |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| CN116726006A (zh) | 2016-08-19 | 2023-09-12 | 阿拉西斯医药公司 | 眼科药物组合物及其相关用途 |
| WO2018054489A1 (en) * | 2016-09-23 | 2018-03-29 | Hallboeoek Finn | Pharmacological treatment of myopia |
| AU2018304450B2 (en) | 2017-07-20 | 2024-05-16 | Seinda Pharmaceutical Guangzhou Corporation | Composition and methods for the treatment of myopia |
| CA3081482A1 (en) * | 2017-11-17 | 2019-05-23 | Cellix Bio Private Limited | Compounds, compositions and methods for treatment of eye disorders and skin diseases |
| CN111372576A (zh) | 2017-11-17 | 2020-07-03 | 塞尔利克斯生物私人有限公司 | 用于治疗眼部病症的组合物和方法 |
| CA3162141A1 (en) | 2018-04-24 | 2019-10-31 | Allergan, Inc. | Presbyopia treatments |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| JP2022508715A (ja) * | 2018-10-15 | 2022-01-19 | オキュフィア・ファーマ・インコーポレイテッド | 緑内障および関連状態の処置のための方法および組成物 |
| AU2019366451A1 (en) * | 2018-10-26 | 2021-05-20 | Ocuphire Pharma, Inc. | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
| US20200297720A1 (en) * | 2019-03-22 | 2020-09-24 | Baradaina LLC | Methods of Treating Eye Disorders |
| CA3138510A1 (en) * | 2019-05-08 | 2020-11-12 | Harrow Ip, Llc | Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof |
| CN114585365A (zh) * | 2019-06-10 | 2022-06-03 | 视觉治疗股份有限公司 | 在假晶状体患者中使用拟副交感神经药物单独或与一种或多种α激动剂组合以产生多焦点 |
| WO2020252061A1 (en) | 2019-06-10 | 2020-12-17 | Visus Therapeutics, Inc. | Carabachol-bromonidine formulation to enhance anti-presbyopia effects |
| MX2020012116A (es) * | 2020-11-12 | 2022-08-09 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia. |
| CA3216328A1 (en) * | 2021-04-23 | 2022-10-27 | Ocuphire Pharma, Inc. | Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions |
| CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3883225A (en) * | 1972-11-06 | 1975-05-13 | Donald S Rehm | Methods and apparatus for treating acquired myopia and similar or related eye conditions |
| US4136177A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Xanthan gum therapeutic compositions |
| US5360801A (en) * | 1989-06-21 | 1994-11-01 | The Trustees Of The University Of Pennsylvania | Pharmacological stimulation of eye growth |
| AU4653993A (en) * | 1992-07-02 | 1994-01-31 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| KR20010034461A (ko) * | 1998-01-28 | 2001-04-25 | 요시다 쇼지 | 시기능 장해의 예방 또는 치료제 |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6277855B1 (en) * | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20040116524A1 (en) * | 2002-02-04 | 2004-06-17 | Cohen Ben Z. | Method of administering opthalmic fluids |
| US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| KR20060109947A (ko) * | 2003-11-20 | 2006-10-23 | 오쎄라 파마슈티걸즈, 인크. | 황반 변성 및 다른 안과 질환의 개선 |
| MXPA03011987A (es) * | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| US7479277B2 (en) * | 2005-02-24 | 2009-01-20 | Wisconsin Alumni Research Foundation | Method for reducing intraocular pressure using integrin-linked kinase inhibitor |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| ATE439863T1 (de) | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| WO2008083118A1 (en) | 2006-12-26 | 2008-07-10 | Qlt Plug Delivery, Inc. | Drug delivery implants for inhibition of optical defects |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
-
2007
- 2007-12-15 GB GBGB0724558.2A patent/GB0724558D0/en not_active Ceased
-
2008
- 2008-12-15 CA CA2747095A patent/CA2747095C/en not_active Expired - Fee Related
- 2008-12-15 EP EP16000001.4A patent/EP3031457B1/en active Active
- 2008-12-15 US US12/334,916 patent/US20090156606A1/en not_active Abandoned
- 2008-12-15 EP EP08861490.4A patent/EP2242487B1/en not_active Not-in-force
- 2008-12-15 ES ES08861490.4T patent/ES2572750T3/es active Active
- 2008-12-15 CN CN2008801268956A patent/CN101969940A/zh active Pending
- 2008-12-15 WO PCT/GB2008/004129 patent/WO2009077736A2/en active Application Filing
- 2008-12-15 AU AU2008337350A patent/AU2008337350A1/en not_active Abandoned
- 2008-12-15 ES ES16000001T patent/ES2725002T3/es active Active
- 2008-12-15 BR BRPI0821683A patent/BRPI0821683B8/pt active IP Right Grant
- 2008-12-15 EP EP19000065.3A patent/EP3505169B1/en active Active
-
2010
- 2010-07-15 ZA ZA2010/05026A patent/ZA201005026B/en unknown
-
2012
- 2012-12-03 US US13/692,257 patent/US8829037B2/en active Active
-
2014
- 2014-09-08 US US14/479,852 patent/US9623007B2/en active Active
-
2017
- 2017-04-18 US US15/489,950 patent/US11278545B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3505169A1 (en) | 2019-07-03 |
| BRPI0821683A2 (pt) | 2015-06-16 |
| EP3031457A1 (en) | 2016-06-15 |
| WO2009077736A4 (en) | 2010-02-25 |
| AU2008337350A1 (en) | 2009-06-25 |
| GB0724558D0 (en) | 2008-01-30 |
| BRPI0821683B1 (pt) | 2019-11-05 |
| US20090156606A1 (en) | 2009-06-18 |
| EP3031457B1 (en) | 2019-02-06 |
| CA2747095A1 (en) | 2009-06-25 |
| US20170216281A1 (en) | 2017-08-03 |
| WO2009077736A2 (en) | 2009-06-25 |
| US8829037B2 (en) | 2014-09-09 |
| US20130096131A1 (en) | 2013-04-18 |
| US20140378519A1 (en) | 2014-12-25 |
| EP3505169B1 (en) | 2021-11-03 |
| CN101969940A (zh) | 2011-02-09 |
| WO2009077736A3 (en) | 2009-12-30 |
| EP2242487B1 (en) | 2016-02-24 |
| BRPI0821683B8 (pt) | 2021-05-25 |
| ZA201005026B (en) | 2011-03-30 |
| US11278545B2 (en) | 2022-03-22 |
| CA2747095C (en) | 2020-02-18 |
| US9623007B2 (en) | 2017-04-18 |
| ES2725002T3 (es) | 2019-09-18 |
| EP2242487A2 (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2572750T3 (es) | Un medicamento que comprende pilocarpina y dapiprazol | |
| ES2719250T3 (es) | Formulación oftálmica y método para mitigar la presbicia | |
| US8679521B2 (en) | Treatment of ophthalmic conditions | |
| AU2018282415B2 (en) | Optical correction | |
| Roncone | Toric soft contact lens fit in a postoperative LASIK keratoectasia patient with high and irregular astigmatism | |
| DK1706094T3 (en) | TREATMENT OF Ophthalmological conditions | |
| Boucher | Long-term use of saturn II and softperm contact lenses for keratoplasty and keratoconus: a case report | |
| Devgan | New multifocal IOLs offer excellent results. | |
| Hsiao et al. | Comparison of soft contact lens and rigid gas permeable lens fitting after laser in situ keratomileusis (LASIK) |